Skip to main content

Table 4 Action plan results: outcomes in treatment phase I (neoadjuvant treatment)

From: Improving quality of care and clinical outcomes for rectal cancer through clinical audits in a multicentre cancer care organisation

 

Total patients

Centre A

Centre B

Centre C

ACOR-1

(N = 120)

ACOR-2

(N = 120)

p-value

ACOR-1

(N = 40)

ACOR-2

(N = 40)

p-value

ACOR-1

(N = 120)

ACOR-2

(N = 120)

p-value

ACOR-1

(N = 40)

ACOR-2

(N = 40)

p-value

Planned treatment

 RT + chemo

115 (95.8%)

107 (89.2%)

0.086

37 (92.5%)

34 (85%)

0.48

39 (97.5%)

39 (97.5%)

>  0.99

39 (97.5%)

34 (85%)

0.11

 RT

5 (4.2%)

13 (10.8%)

3 (7.5%)

6 (15%)

1 (2.5%)

1 (2.5%)

1 (2.5%)

6 (15%)

Type of radiotherapy

 LCRT

108 (90%)

102 (85%)

0.33

36 (90%)

32 (80%)

0.35

40 (100%)

38 (95%)

0.47

32 (80%)

32 (80%)

>  0.99

 SCRT

12 (10%)

18 (15%)

4 (10%)

8 (20%)

0 (0%)

2 (5%)

8 (20%)

8 (20%)

Type of indicated technology

 3D

117 (97.5%)

95 (79.2%)

<  0.001‡

40 (100%)

23 (57.5%)

<  0.001‡

40 (100%)

38 (95%)

0.47

37 (92.5%)

34 (85%)

0.48

 VMAT

3 (2.5%)

25 (20.8%)

0 (0%)

17 (42.5%)

0 (0%)

2 (5%)

3 (7.5%)

6 (15%)

Total dosage administered

 25 Gy

12 (10.3%)

18 (15.3%)

0.034*

4 (10.3%)

8 (21.1%)

<  0.001‡

0 (0%)

2 (5%)

0.36

8 (21.1%)

8 (20%)

0.57

 45 Gy

34 (29.1%)

15 (12.7%)

34 (87.2%)

14 (36.8%)

0 (0%)

0 (0%)

0 (0%)

1 (2.5%)

 50 Gy

3 (2.6%)

6 (5.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

3 (7.9%)

6 (15%)

 50.4 Gy

63 (53.8%)

74 (62.7%)

1 (2.6%)

16 (42.1%)

35 (87.5%)

33 (82.5%)

27 (71.1%)

25 (62.5%)

 54 Gy

5 (4.3%)

5 (4.2%)

0 (0%)

0 (0%)

5 (12.5%)

5 (12.5%)

0 (0%)

0 (0%)

Prolongation of treatment time (if SCRT)

  < 3 days

12 (100%)

17 (94.4%)

>  0.99

4 (100%)

8 (100%)

0.25

0 (NaN%)

2 (100%)

0.16

8 (100%)

7 (87.5%)

>  0.99

 3–5 days

0 (0%)

1 (5.6%)

0 (0%)

0 (0%)

0 (NaN%)

0 (0%)

0 (0%)

1 (12.5%)

Prolongation of treatment time (if LCRT)

  < 3 days

62 (57.4%)

58 (56.9%)

0.96

19 (52.8%)

20 (62.5%)

0.22

31 (77.5%)

27 (71.1%)

0.53

12 (37.5%)

11 (34.4%)

0.90

 3–5 days

32 (29.6%)

31 (30.4%)

11 (30.6%)

10 (31.2%)

9 (22.5%)

9 (23.7%)

12 (37.5%)

12 (37.5%)

 6–7 days

4 (3.7%)

5 (4.9%)

0 (0%)

1 (3.1%)

0 (0%)

1 (2.6%)

4 (12.5%)

3 (9.4%)

  > 7 days

10 (9.3%)

8 (7.8%)

6 (16.7%)

1 (3.1%)

0 (0%)

1 (2.6%)

4 (12.5%)

6 (18.8%)

Week day when treatment was finalised

 Monday

17 (14.2%)

7 (5.8%)

0.24

6 (15%)

1 (2.5%)

0.16

6 (15%)

3 (7.5%)

0.68

5 (12.5%)

3 (7.5%)

0.28

 Tuesday

24 (20%)

22 (18.3%)

11 (27.5%)

11 (27.5%)

5 (12.5%)

6 (15%)

8 (20%)

5 (12.5%)

 Wednesday

13 (10.8%)

12 (10%)

5 (12.5%)

5 (12.5%)

2 (5%)

1 (2.5%)

6 (15%)

6 (15%)

 Thursday

24 (20%)

27 (22.5%)

8 (20%)

5 (12.5%)

11 (27.5%)

9 (22.5%)

5 (12.5%)

13 (32.5%)

 Friday

42 (35%)

52 (43.3%)

10 (25%)

18 (45%)

16 (40%)

21 (52.5%)

16 (40%)

13 (32.5%)

  1. ACOR clinical audit for radiation oncology, LCRT long-course radiotherapy, SCRT short-course radiotherapy, RT radiotherapy, VMAT volumetric modulated arc therapy
  2. *p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001